The European Investment Bank has been promoting biotechnology in Europe for years - for example Biontech.
President Werner Hoyer explains why there is still a problem with the vaccine supply and why even large countries like Germany depend on the help of others.
WORLD:
Did Europe miss the vaccination start?
Hoyer:
I don't like taking part in this debate.
Now all of them are amateur virologists and have always wanted to know that Biontech is the solution.
But the situation wasn't that clear ten months ago.
That is why it would have been a mistake if the federal government or the EU Commission had placed everything on one card with their orders and only ordered from one provider.
WELT:
The result is now that there is an effective vaccine from Europe that is vaccinated much more quickly elsewhere.